Epclusa is a prescribed drug for treating chronic Hepatitis C Virus (HCV) infection. This is a combination tablet with two direct-acting antiviral agents: Sofosbuvir (400 mg) and Velpatasvir (100 mg), each at a fixed dose. Produced by Gilead Sciences, Epclusa has significantly altered the treatment landscape for Hepatitis C by providing a pan-genotypic regimen that is effective against all six major genotypes of the virus.

This oral medication taken once a day has emerged as a cornerstone in antiviral therapy because of its high cure rates, relatively brief treatment duration, and fewer side effects compared to older interferon-based treatments.

Mechanism of Action

Epclusa acts by focusing on two crucial proteins necessary for the replication of the Hepatitis C virus:

Sofosbuvir functions as a nucleotide analog inhibitor that targets the HCV NS5B RNA-dependent RNA polymerase. It inhibits the enzyme’s action, thereby stopping the virus from replicating its RNA.

Velpatasvir inhibits the HCV NS5A protein. NS5A plays a vital role in viral replication, assembly, and secretion processes. Velpatasvir disrupts various phases of the HCV lifecycle by inhibiting this protein.

The two agents work together in a synergistic manner to prevent the virus from replicating in the liver, which allows the immune system to clear the infection more efficiently.

Indications

Epclusa is approved for treating chronic HCV infection in adults and pediatric patients aged 3 years and above, regardless of whether they have compensated cirrhosis. It works effectively for all genotypes (1-6) and is frequently advised for:

Patients without prior treatment

Individuals suffering from a simultaneous HIV infection

Patients, regardless of whether they have cirrhosis

Patients suffering from decompensated cirrhosis (when combined with ribavirin)

The typical treatment duration is 12 weeks, but this can differ based on the patient’s medical history, liver condition, and additional factors.

Dosage and Administration

Every Epclusa tablet includes:

400 mg Sofosbuvir

100 mg Velpatasvir

The advised dosage is one tablet taken by mouth once a day, regardless of meals.

In patients suffering from decompensated cirrhosis, Epclusa is given together with ribavirin. The dosage of ribavirin is determined by weight and it should be taken with food in split doses.

Efficacy

Clinical studies have demonstrated that Epclusa attains sustained virologic response (SVR) rates exceeding 95% for all genotypes. SVR is achieved when the virus is undetectable in the blood 12 weeks post-treatment completion, which is effectively regarded as a cure.

The efficacy of Epclusa, especially among patients with cirrhosis and those in difficult-to-treat populations, was demonstrated through the ASTRAL clinical trials.

Side Effects

Most patients tolerate Epclusa well. Nevertheless, as with all pharmaceuticals, it can lead to side effects in certain people. Common side effects include:

Headache

Fatigue

Nausea

Insomnia

Diarrhea

When taken with ribavirin, side effects may include anemia, rash, and increased fatigue.

Serious adverse effects are rare but should be reported to a healthcare provider immediately. Liver function should be monitored, especially in patients with advanced liver disease.

Contraindications and Warnings

Sofosbuvir+Velpatasvir 100 mg (Epclusa) is contraindicated in patients taking rifampin, a strong P-glycoprotein inducer that significantly reduces sofosbuvir levels.

Due to the risk of severe bradycardia, it is important to be careful when also giving amiodarone.

In pregnant women, it should only be considered if the potential benefit outweighs the potential risk to the fetus. When combined with ribavirin, pregnancy is strictly contraindicated due to teratogenicity.

No dose adjustment is needed for patients with renal impairment unless the patient is on dialysis.

Drug Interactions

Epclusa may interact with a variety of drugs including:

Antacids and proton pump inhibitors (they reduce the absorption of Velpatasvir)

Patients should inform their healthcare provider of all medications, supplements, and herbs they are taking to avoid potential interactions.

Storage

Epclusa must be kept at room temperature (20°C to 25°C or 68°F to 77°F), protected from moisture and direct sunlight. Keep it out of children’s reach.

Conclusion

Epclusa (Sofosbuvir 400 mg and Velpatasvir 100 mg) marks a significant progress in the treatment of Hepatitis C. Because it can treat all genotypes with a single pill taken once daily over the course of 12 weeks, it is favored by both doctors and patients. Epclusa remains a revolutionary treatment in the battle against chronic Hepatitis C infection, thanks to its elevated cure rates, low toxicity levels, and minimal disruption to daily life.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What are Sofosbuvir and Velpatasvir (Epclusa)?
The combination antiviral medication Sofosbuvir and Velpatasvir (Epclusa) is utilized for the treatment of chronic hepatitis C virus (HCV) infections. It brings together two medications—sofosbuvir (a nucleotide polymerase inhibitor) and velpatasvir (an NS5A inhibitor)—to target various phases of the HCV life cycle and stop the virus from replicating.

2. What is the mechanism of action of Epclusa?
Epclusa functions by blocking two essential enzymes required for the replication of HCV. Sofosbuvir prevents viral replication by inhibiting the NS5B RNA polymerase enzyme, while Velpatasvir targets the NS5A protein, essential for the virus’s replication and assembly. In conjunction, they prevent the virus from disseminating within the body.

3. What condition does Epclusa treat?
Epclusa is mainly utilized for the treatment of chronic hepatitis C virus (HCV) infections in adults. It is effective against various HCV genotypes, making it a flexible choice for managing the condition.

4. What is the method of administration for Epclusa?
Typically, Epclusa is consumed as one oral tablet daily, regardless of meals. While the usual dosage consists of 100 mg of Sofosbuvir and 40 mg of Velpatasvir, the precise dosage may vary based on individual patient factors, including genotype and previous treatment history.

5. What are the common side effects of Epclusa?
Typical adverse effects comprise tiredness, headache, nausea, and sleep issues. Some people may also experience diarrhea, dizziness, or mild liver enzyme elevation. Although serious side effects are uncommon, they can encompass allergic reactions or liver problems.